Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355591 | 0.81 | TP53 (0.49) | POLBMAPT | |
| SCHEMBL18355754 | 0.77 | PDE10A (0.36) | MAPK1HTTSMN1; SMN2POLBMAPT | |
| SCHEMBL9257140 | 0.77 | MAPK1 (0.70) | MAPK1HTTTSHRSMN1; SMN2RAB9A | |
| SCHEMBL338236 | 0.76 | MAPK1 (0.74) | MAPK1HTTTSHRSMN1; SMN2POLB | |
| SCHEMBL7760076 | 0.76 | MAPK1 (0.79) | MAPK1HTTTSHRSMN1; SMN2NPC1 | |
| SCHEMBL18355592 | 0.76 | MAPK1 (0.59) | MAPK1HTTHSD17B10HRH3KCNH2 | |
| SCHEMBL540947 | 0.76 | MAPK1 (1.00) | MAPK1HTTTSHRSMN1; SMN2NPC1 | |
| Bromide SCHEMBL18614520 | 0.75 | MAPK1 (0.57) | MAPK1HTTHSD17B10HRH3KCNH2 | |
| SCHEMBL9263231 | 0.73 | MAPK1 (0.74) | MAPK1HTTTSHRSMN1; SMN2POLB | |
| SCHEMBL13495663 | 0.73 | MAPK1 (0.74) | MAPK1HTTTSHRSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | MAPK1 976/4885HTT 4358/4885TSHR 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.